The global life sciences industry is advancing rapidly. Increased generic competition, the changing patent landscape, evolving regulations, and pricing pressures present new challenges and opportunities for companies across the sector.
Our cross-disciplinary team can steer you through every phase of your life cycle, helping you carefully consider all of your options, and execute effective growth strategies—whether through licensing, M&A deals, or other types of transactions.
And while we have a lot of experience with transactions and litigation for large public companies, we have a passion for helping mid-market and startup companies grow.
The rapidly changing life sciences ecosystem presents a lot of exciting opportunities. We’re focused on helping clients leverage those opportunities and make strategic decisions that maximize their business potential.
The Recorder | February 18, 2022
This column on notable moves within the legal industry across California highlights Los Angeles partner and Life Sciences co-chair Seth Levy for his appointment as Intellectual Property practice group leader.
Pacific Coast Business Times | February 15, 2022
This article features Los Angeles Intellectual Property partner and Life Sciences co-chair Seth Levy for his appointment as the firm’s Intellectual Property practice group leader.
Bloomberg Law | February 10, 2022
This roundup of notable industry news features the appointment of Los Angeles Intellectual Property partner and Life Sciences co-chair Seth Levy as leader of the firm’s IP practice.
Q Voice News | December 09, 2021
The following article covers the successful resolution of a long-running pro bono matter for which NP teamed with the ACLU to represent a transgender woman who was denied access to the women’s locker room at a gym in San Diego on more than 70 occasions. This denial of access clearly violated California’s Unruh Civil Rights Act, which bars discrimination in public accommodations. After more than three years, the parties reached a fair settlement. The NP team working on this case includes Intellectual Property partner and Life Sciences practice co-chair Seth Levy, Labor & Employment partner Michael Lindsay, and alum Erin Holyoke, all of the Los Angeles office.
Advocate | December 09, 2021
The following article covers the successful resolution of a long-running pro bono matter for which NP teamed with the ACLU to represent a transgender woman who was denied access to the women’s locker room at a gym in San Diego on more than 70 occasions. This denial of access clearly violated California’s Unruh Civil Rights Act, which bars discrimination in public accommodations. After more than three years, the parties reached a fair settlement. The NP team working on this case includes Intellectual Property partner and Life Sciences practice co-chair Seth Levy, Labor & Employment partner Michael Lindsay, and alum Erin Holyoke, all of the Los Angeles office.
Technology Transfer Tactics | February 22, 2021
Life Sciences practice co-chair and Los Angeles Intellectual Property partner Seth Levy contributed this article on how litigation funding can address some of the more significant challenges for a growing number of universities pursuing patent enforcement campaigns.
Life Sciences Intellectual Property Review | February 18, 2021
Life Sciences practice co-chair and Los Angeles Intellectual Property partner Seth Levy provides third-party commentary on sovereign immunity for disputes involving patents owned by state universities, after the University of Texas lost an appeal to review a ruling preventing it from using sovereign immunity to shield patents from inter partes reviews.
Click here to read the article.
World Intellectual Property Review | February 17, 2021
Los Angeles Intellectual Property partner and Life Sciences practice co-chair Seth Levy is featured in this Q&A related to diversity in the intellectual property field, with a particular focus on LGBT+ History Month.
Supply Chain Brain | October 05, 2020
The following article covers the U.S. International Trade Commission’s second investigation into leading retailers and suppliers of filament LED lighting products, based on a complaint filed by Nixon Peabody on behalf of the Regents of the University of California (UC). Supply Chain Brain quotes Los Angeles Intellectual Property partner Seth Levy extensively on the expanded patent enforcement campaign. The NP team representing UC is led by Seth and Los Angeles Intellectual Property partner Shawn Hansen.
Intellectual Property Magazine | October 01, 2020
Intellectual Property partner and Life Sciences Practice co-chair Seth Levy and Intellectual Property counsel Peter Wied, both of Los Angeles, contributed this article, based on their alert, which examines the Gensetix Inc v Baylor College of Medicine case and a recent ruling to allow an infringement case to proceed without the state university patent owner’s involvement.
Bloomberg Law | September 30, 2020
This article covers the U.S. International Trade Commission’s institution of a second investigation into leading retailers and suppliers of filament LED lighting products, based on a complaint NP filed on behalf of the Regents of the University of California (UC). Los Angeles Intellectual Property partners Seth Levy and Shawn Hansen are leading the NP team in UC’s LED patent enforcement campaign.
World IP Review | September 30, 2020
The following article covers the U.S. International Trade Commission’s second investigation into leading retailers and suppliers of filament LED lighting products, based on a complaint filed by Nixon Peabody on behalf of the Regents of the University of California (UC). Supply Chain Brain quotes Los Angeles Intellectual Property partner Seth Levy extensively on the expanded patent enforcement campaign. The NP team representing UC is led by Seth and Los Angeles Intellectual Property partner Shawn Hansen.
Law360 | September 22, 2020
This article covers a trial to consider the amount of damages to be awarded to Millennium Pharmaceuticals for being fraudulently induced into investing more than $100 million into a spinoff of Harpoon Therapeutics. The story mentions Chicago Complex Commercial Disputes partners John Ruskusky and Lisa Sullivan for representing Millennium.
Modern Healthcare | July 28, 2020
In this article on the Department of Health and Human Services Office of Inspector General’s advisory opinion that will expand national nonprofit and client RIP Medical Debt’s services, Long Island Health Care partner Michele Masucci is quoted on the legal nuances of the advisory opinion and anti-kickback concerns.
Law360 | July 24, 2020
Complex Commercial Disputes co-practice group leader and Boston partner Steve LaRose and Manchester associate Kierstan Schultz were mentioned in this article for representing Aetna in a suit regarding coverage for medical device manufacturer Conformis’ customized total knee implants.
Nature Biotechnology | July 08, 2020
Boston Intellectual Property partner Mark FitzGerald co-authored this journal article on microbiome therapeutics, and how two U.S. Supreme Court decisions have redefined the scope of which natural phenomena—including microbiome therapeutics—are patent eligible.
Law360 | June 25, 2020
This article, covering a federal judge’s dismissal of claims against NP client Bayer Corp. related to the company’s Essure birth control device, mentions Buffalo Complex Commercial Disputes partner Vivian Quinn and counsel Tracey Scarpello for representing Bayer.
Intellectual Property & Technology Law Journal | May 01, 2020
Intellectual Property partner Mark FitzGerald in Boston and associate Matt Kitces in Washington, D.C. contributed this article examining the post-grant review challenge of a U.S. patent related microbiomes and the treatment of cancer. The result could provide an indication of how microbiome-related patents will fare when challenged for validity. Click here for the full article.
Microbiome Times | April 29, 2020
Boston Intellectual Property partners Mark FitzGerald and David Resnick co-authored this article analyzing a recent decision by the U.S. Patent Trial and Appeal Board to invalidate a University of Chicago U.S. microbiome patent. The authors note some positive aspects of that decision within the microbiome community, as it provides increased definition around what they can protect with patents.
IAM | April 02, 2020
Boston Intellectual Property partner Mark FitzGerald discusses how the microbiome—the collection of microbes that occupy the human body—has become an increasingly fruitful source of insights for life sciences researchers looking to develop new therapeutics.
Law360 | March 06, 2020
This article mentions Boston Government Investigations and White-Collar Defense partners Hannah Bornstein and Mark Seltzer for their representation of the defendants in a False Claims Act suit centering on faulty hip replacement devices. The defendants have argued the suit should be dismissed on the grounds that confidential information was used in the complaint.
Intellectual Property & Technology Law Journal | December 05, 2019
Intellectual Property associates Sydney Pritchett, Ben Rosborough and Ravi Braich authored this patent alert about remaining questions and uncertainty following the U.S. Supreme Court ‘s ruling in Helsinn Healthcare S.A. v. Teva Pharmaceuticals U.S.
Modern Healthcare | September 07, 2019
This article discussing the 21st Century Cures Act’s ongoing impact on the Food and Drug Administration’s approval process quotes Boston Government Investigations and White Collar Defense partner Hannah Bornstein and Chicago Health Care partner Valerie Montague.
Defense Research Institute | September 04, 2019
Complex Commercial Disputes partner Vivian Quinn and associate Tracey Scarpello, both of the Buffalo office, co-wrote this article in the Defense Research Institute’s publication, analyzing the impact of the ascertainability requirement on pharmaceutical and medical device class actions.
Boston Business Journal | August 08, 2019
This story quotes Boston Intellectual Property partner David Resnick on best practices and challenges facing microbiome companies, which create novel disease-fighting treatments from naturally occurring substances, as they try to patent their innovations.
Reuters Legal | July 25, 2019
This story mentions Boston Government Investigations and White Collar Defense partner Mark Seltzer for his representation of GlaxoSmithKline in an ongoing matter regarding the drugmaker’s antinausea medication, Zofran.
Law360 | July 10, 2019
The following articles mention Boston Government Investigations and White Collar Defense partners Mark Seltzer and Brian French for their representation of GlaxoSmithKline in an ongoing matter related to the pharmaceutical company’s anti-nausea drug Zofran. One of the issues is whether federal law pre-empts state law in the case.
Reuters Legal | July 10, 2019
The following articles mention Boston Government Investigations and White Collar Defense partners Mark Seltzer and Brian French for their representation of GlaxoSmithKline in an ongoing matter related to the pharmaceutical company’s anti-nausea drug Zofran. One of the issues is whether federal law pre-empts state law in the case.
Reuters Legal | June 04, 2019
This article mentions Boston Government Investigations and White Collar Defense partner Mark Seltzer for his representation of GlaxoSmithKline in an ongoing matter related to its anti-nausea medication Zofran.
Partner
Leader, Intellectual Property Practice
Co-chair, Life Sciences Practice
Phone: 213-629-6161
Partner
Co-chair, Life Sciences Practice
Strategic Impact Partner
Phone: 213-629-6175